Cyclophosphamide pharmacokinetics in children
| Autor: | Alan V. Boddy, M. J. Tasso, L. Price, S. M. Yule, Ruth Wyllie, A. D. J. Pearson, Michael Cole, Jeffrey R. Idle |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Male
Adolescent Cyclophosphamide Allopurinol Pharmacology Pharmacokinetics In vivo Neoplasms medicine Humans Drug Interactions Pharmacology (medical) Child Chlorpromazine Antineoplastic Agents Alkylating Dexamethasone Volume of distribution business.industry Therapeutic effect Age Factors Infant Child Preschool Female business Half-Life medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 0306-5251 |
| Popis: | 1. Cyclophosphamide pharmacokinetics were measured in 38 children with cancer. 2. A high degree of inter-patient variation was seen in all pharmacokinetic parameters. Cyclophosphamide half-life varied between 1.1 and 16.8 h, clearance varied between 1.2 and 10.61 h-1 m-2 and volume of distribution varied between 0.26 and 1.48 1 kg-1. 3. The half-life of cyclophosphamide was prolonged at high dose levels (P = 0.008). 4. Children who had received prior treatment with dexamethasone showed a mean increase in clearance of 2.51 h-1 m-2 (P = 0.001) presumably as a result of CYP450 enzyme induction. 5. Treatment with allopurinol or chlorpromazine was associated with a significant increase in cyclophosphamide half-life (P < 0.001 in both cases). 6. Dose and concurrent treatment may influence cyclophosphamide metabolism in vivo and thus potentially alter the drugs therapeutic effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text